AbbVie Inc. (ABBV) operating KPIs
ABBVNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026Score 10/3094% above fair value
$294.89+4.10 (+1.41%)
Close on Oct 30, 2026Market cap $521.11BP/E 83.3Yield 2.26%
Latest, Q2 2026
4,291
Period ended Jun 30, 2026
Change on a year earlier
-1.3%
4,346 in Q2 2025
History
58 quarters
Since Q1 2012
Sources
51
Documents cited below
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Cost of products sold ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | 4,291 | -1.3% | Form 10-Q (filed 2026-08-03) ↗ |
| Q1 2026 | Mar 31, 2026 | 4,218 | +5.4% | Form 10-Q (filed 2026-05-08) ↗ |
| Q4 2025 | Dec 31, 2025 | 4,552 | +3.5% | Form 10-K (filed 2026-02-20) ↗ |
| Q3 2025 | Sep 30, 2025 | 5,304 | +25.9% | Form 10-Q (filed 2025-11-04) ↗ |
| Q2 2025 | Jun 30, 2025 | 4,346 | +3.4% | Form 10-Q (filed 2025-08-04) ↗ |
| Q1 2025 | Mar 31, 2025 | 4,002 | -2.2% | Form 10-Q (filed 2025-05-09) ↗ |
| Q4 2024 | Dec 31, 2024 | 4,396 | -22.9% | Form 10-K (filed 2025-02-14) ↗ |
| Q3 2024 | Sep 30, 2024 | 4,212 | -35.1% | Form 10-Q (filed 2024-11-04) ↗ |
| Q2 2024 | Jun 30, 2024 | 4,202 | -0.9% | Form 10-Q (filed 2024-08-07) ↗ |
| Q1 2024 | Mar 31, 2024 | 4,094 | +2.7% | Form 10-Q (filed 2024-05-03) ↗ |
| Q4 2023 | Dec 31, 2023 | 5,704 | +36.8% | Form 10-K (filed 2024-02-20) ↗ |
| Q3 2023 | Sep 30, 2023 | 6,485 | +29.1% | Form 10-Q (filed 2023-11-06) ↗ |
| Q2 2023 | Jun 30, 2023 | 4,240 | +1.7% | Form 10-Q (filed 2023-08-07) ↗ |
| Q1 2023 | Mar 31, 2023 | 3,986 | -1.6% | Form 10-Q (filed 2023-05-05) ↗ |
| Q4 2022 | Dec 31, 2022 | 4,170 | -3.5% | Form 10-K (filed 2023-02-17) ↗ |
| Q3 2022 | Sep 30, 2022 | 5,022 | +14.4% | Form 10-Q (filed 2022-11-04) ↗ |
| Q2 2022 | Jun 30, 2022 | 4,170 | -7.8% | Form 10-Q (filed 2022-08-04) ↗ |
| Q1 2022 | Mar 31, 2022 | 4,052 | -3.8% | Form 10-Q (filed 2022-05-06) ↗ |
| Q4 2021 | Dec 31, 2021 | 4,320 | -7.8% | Form 10-K (filed 2022-02-18) ↗ |
| Q3 2021 | Sep 30, 2021 | 4,390 | -13.1% | Form 10-Q (filed 2021-11-02) ↗ |
| Q2 2021 | Jun 30, 2021 | 4,523 | +21.9% | Form 10-Q (filed 2021-08-02) ↗ |
| Q1 2021 | Mar 31, 2021 | 4,213 | +116.9% | Form 10-Q (filed 2021-05-07) ↗ |
| Q4 2020 | Dec 31, 2020 | 4,684 | +133.5% | Form 10-K (filed 2021-02-19) ↗ |
| Q3 2020 | Sep 30, 2020 | 5,050 | +163.0% | Form 10-Q (filed 2020-11-04) ↗ |
| Q2 2020 | Jun 30, 2020 | 3,711 | +104.0% | Form 10-Q (filed 2020-08-04) ↗ |
| Q1 2020 | Mar 31, 2020 | 1,942 | +14.6% | Form 10-Q (filed 2020-05-08) ↗ |
| Q4 2019 | Dec 31, 2019 | 2,006 | -0.8% | Form 10-K (filed 2020-02-21) ↗ |
| Q3 2019 | Sep 30, 2019 | 1,920 | +4.6% | Form 10-Q (filed 2019-11-06) ↗ |
| Q2 2019 | Jun 30, 2019 | 1,819 | -5.9% | Form 10-Q (filed 2019-08-05) ↗ |
| Q1 2019 | Mar 31, 2019 | 1,694 | -12.1% | Form 10-Q (filed 2019-05-03) ↗ |
| Q4 2018 | Dec 31, 2018 | 2,022 | -11.4% | Form 10-K (filed 2019-02-27) ↗ |
| Q3 2018 | Sep 30, 2018 | 1,835 | +13.6% | Form 10-Q (filed 2018-11-07) ↗ |
| Q2 2018 | Jun 30, 2018 | 1,934 | +26.5% | Form 10-Q (filed 2018-08-07) ↗ |
| Q1 2018 | Mar 31, 2018 | 1,927 | +19.2% | Form 10-Q (filed 2018-05-04) ↗ |
| Q4 2017 | Dec 31, 2017 | 2,281 | +46.8% | Form 10-K (filed 2019-02-27) ↗ |
| Q3 2017 | Sep 30, 2017 | 1,616 | +7.4% | Form 10-Q (filed 2017-11-07) ↗ |
| Q2 2017 | Jun 30, 2017 | 1,529 | +8.8% | Form 10-Q (filed 2018-08-07) ↗ |
| Q1 2017 | Mar 31, 2017 | 1,616 | +18.0% | Form 10-Q (filed 2017-05-05) ↗ |
| Q4 2016 | Dec 31, 2016 | 1,554 | +5.4% | Form 10-K (filed 2019-02-27) ↗ |
| Q3 2016 | Sep 30, 2016 | 1,504 | +28.9% | Form 10-Q (filed 2016-11-07) ↗ |
| Q2 2016 | Jun 30, 2016 | 1,405 | +53.4% | Form 10-Q (filed 2016-08-05) ↗ |
| Q1 2016 | Mar 31, 2016 | 1,369 | +45.3% | Form 10-Q (filed 2016-05-06) ↗ |
| Q4 2015 | Dec 31, 2015 | 1,475 | +31.8% | Form 10-K (filed 2016-02-19) ↗ |
| Q3 2015 | Sep 30, 2015 | 1,167 | +6.7% | Form 10-Q (filed 2015-11-06) ↗ |
| Q2 2015 | Jun 30, 2015 | 916 | -17.7% | Form 10-Q (filed 2015-08-07) ↗ |
| Q1 2015 | Mar 31, 2015 | 942 | -14.4% | Form 10-Q (filed 2015-05-08) ↗ |
| Q4 2014 | Dec 31, 2014 | 1,119 | -12.7% | Form 10-K (filed 2015-02-20) ↗ |
| Q3 2014 | Sep 30, 2014 | 1,094 | +0.2% | Form 10-Q (filed 2014-11-07) ↗ |
| Q2 2014 | Jun 30, 2014 | 1,113 | +5.6% | Form 10-Q (filed 2014-08-07) ↗ |
| Q1 2014 | Mar 31, 2014 | 1,100 | -4.6% | Form 10-Q (filed 2014-05-09) ↗ |
| Q4 2013 | Dec 31, 2013 | 1,282 | +1.3% | Form 10-K (filed 2014-02-21) ↗ |
| Q3 2013 | Sep 30, 2013 | 1,092 | +7.7% | Form 10-Q (filed 2013-11-12) ↗ |
| Q2 2013 | Jun 30, 2013 | 1,054 | -1.8% | Form 10-Q (filed 2013-08-09) ↗ |
| Q1 2013 | Mar 31, 2013 | 1,153 | -0.3% | Form 10-Q (filed 2013-05-08) ↗ |
| Q4 2012 | Dec 31, 2012 | 1,265 | – | Form 10-K (filed 2014-02-21) ↗ |
| Q3 2012 | Sep 30, 2012 | 1,014 | – | Form 10-Q (filed 2013-11-12) ↗ |
| Q2 2012 | Jun 30, 2012 | 1,073 | – | Form 10-Q (filed 2013-08-09) ↗ |
| Q1 2012 | Mar 31, 2012 | 1,156 | – | Form 10-Q (filed 2013-05-08) ↗ |
Cite this data
StockData. (2026). AbbVie Cost of products sold ($M) ($M), quarterly Q1 2012–Q2 2026 [Data set]. Compiled from AbbVie SEC filings and investor materials. https://stockdatahq.com/stocks/abbv/kpis/fs_cor
See every metric in the AbbVie KPI table. Data updated Oct 26, 2026.